Introduction：Basic information about Plazomicin CAS 1154757-24-0, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Plazomicin Basic information
| Product Name: | Plazomicin |
| Synonyms: | ACHN 490;O-2-AMino-2,3,4,6-tetradeoxy-6-[(2-hydroxyethyl)aMino]-α-D-glycero-hex-4-enopyranosyl-(1→4)-O-[3-deoxy-4-C-Methyl-3-(MethylaMino)-β-L-arabinopyranosyl-(1→6)]-N1-[(2S)-4-aMino-2-hydroxy-1-oxobutyl]-2-deoxy-D-streptaMine;PlazoMicin;IYDYFVUFSPQPPV-BPUQVFSTSA-N;D-Streptamine, O-2-amino-2,3,4,6-tetradeoxy-6-[(2-hydroxyethyl)amino]-α-D-glycero-hex-4-enopyranosyl-(1→4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1→6)]-N1-[(2S)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy-;Plazomicin API;Pirimicarb Impurity 9 (Ethirimol);Sisomicin Impurity 10 |
| CAS: | 1154757-24-0 |
| MF: | C25H48N6O10 |
| MW: | 592.68282 |
| EINECS: | |
| Product Categories: | Amines;Intermediates & Fine Chemicals;Oligosaccharides;Pharmaceuticals |
| Mol File: | 1154757-24-0.mol |
|
Plazomicin Chemical Properties
| Melting point | >185°C (dec.) |
| Boiling point | 896.4±65.0 °C(Predicted) |
| density | 1.40±0.1 g/cm3(Predicted) |
| storage temp. | Hygroscopic, -20°C Freezer, Under inert atmosphere |
| solubility | Water (Slightly) |
| pka | 13.11±0.20(Predicted) |
| form | Solid |
| color | Pale Yellow |
Safety Information
Plazomicin Usage And Synthesis
| Description | Plazomicin (PLZ) is a novel aminoglycoside approved by the U.S. Food and Drug Administration (FDA) for the treatment of complicated urinary tract infections (cUTI, including acute pyelonephritis) in adults due to multidrug-resistant carbapenem-resistant Enterobacterales (CRE) or extended-spectrum beta-lactamase (ESBL) producing bacteria. Despite the FDA Black Box Warning for aminoglycoside class effects, PLZ exhibited a favourable safety profile with decreased adverse effects in the largest in-human trials. In vitro, activity of PLZ, in comparison with that of other aminoglycosides, was found to be excellent, with 92.3% to 98.0% overall susceptibility in Enterobacterales, including CRE. Recently, PLZ was also shown to be active against certain multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative pathogens for which limited treatment options are left[1-2]. |
| Uses | Plazomicin (ACHN 490) is a potent aminoglycoside antibiotic in the fight against antimicrobial resistance. Plazomicin has in vitro activity against several multi-drug-resistant organisms, including carbapenem-resistant Enterobacteriaceae. Plazomicin has the potential to be used for multi-drug-resistant complicated urinary tract infections (cUTIs) or in combination for serious carbapenem-resistant Enterobacteriaceae infections[1]. |
| References | [1] Kristy M Shaeer. “Plazomicin: A Next-Generation Aminoglycoside.” Pharmacotherapy 39 1 (2019): 77–93.
[2] Laurine S Blanchard. “Multicenter Clinical Evaluation of ETEST Plazomicin (PLZ) for Susceptibility Testing of Enterobacterales.” Journal of Clinical Microbiology 60 1 (2022): e0183121. |
Plazomicin Preparation Products And Raw materials
